MAGE genes: Prognostic indicators in AL amyloidosis patients

Liu, Yang; Wen, Lei; Ma, Ling; Kang, Ying; Liu, Kai‐Yan; Huang, Xiao‐Jun; Ruan, Guo‐Rui; Lu, Jin

doi:10.1111/jcmm.14475

Title: MAGE genes: Prognostic indicators in AL amyloidosis patients

Journal Article · 20 June 2019 · Journal of Cellular and Molecular Medicine

DOI: https://doi.org/10.1111/jcmm.14475 · OSTI ID:1560211

^[1]; Wen, Lei ^[1]; Ma, Ling ^[1]; Kang, Ying ^[1];

^[1];

^[2]; Ruan, Guo‐Rui ^[1]; Lu, Jin ^[3]

Peking University People's Hospital, Peking University Institute of Hematology Beijing China, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation Beijing China, Collaborative Innovation Center of Hematology, Peking University Beijing China
Peking University People's Hospital, Peking University Institute of Hematology Beijing China, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation Beijing China, Collaborative Innovation Center of Hematology, Peking University Beijing China, Peking‐Tsinghua Center for Life Sciences Academy for Advanced Interdisciplinary Studies, Peking University Beijing China, Collaborative Innovation Center of Hematology Soochow University Suzhou China
Peking University People's Hospital, Peking University Institute of Hematology Beijing China, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation Beijing China, Collaborative Innovation Center of Hematology, Peking University Beijing China, Collaborative Innovation Center of Hematology Soochow University Suzhou China

Abstract A high frequency of MAGE‐CT (cancer testis) antigens are expressed in Multiple Myeloma (MM) patients; however, in other plasma cell dyscrasias, their potential function remains unclear. We measured the expression of MAGE‐CT genes (MAGE‐C1/CT7, MAGE‐A3, MAGE‐C2/CT10) in 105 newly diagnosed amyloid light‐chain (AL) amyloidosis patients between June 2013 and January 2018 at Peking University People's Hospital using real‐time quantitative polymerase chain reaction. In the newly diagnosed AL patients, the positive expression rates of patients with MAGE‐C1/CT7, MAGE‐C2/CT10 and MAGE‐A3 were 83.8% (88/105), 56.71% (38/67) and 22.0% (13/59) respectively. There was no significant correlation between organ propensity and MAGE‐CT gene expression. Changes in the MAGE‐C1/CT7 levels were consistent with a therapeutic effect. The expression levels of MAGE‐C1/CT7, MAGE‐C2/CT10 and MAGE‐A3 provide potentially effective clinical indicators for auxiliary diagnoses and monitoring treatment efficacy in AL amyloidosis patients.

View Journal Article

Cite

Export

Save

Sponsoring Organization:: USDOE

OSTI ID:: 1560211

Alternate ID(s):: OSTI ID: 1560212

Journal Information:: Journal of Cellular and Molecular Medicine, Journal Name: Journal of Cellular and Molecular Medicine Vol. 23 Journal Issue: 8; ISSN 1582-1838

Publisher:: Wiley-BlackwellCopyright Statement

Country of Publication:: Country unknown/Code not available

Language:: English

Citation Metrics:

Cited by: 3 works

Citation information provided by
Web of Science

References (32)

Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group Fernández de Larrea, C.; Kyle, R. A.; Durie, B. G. M. Leukemia, Vol. 27, Issue 4 https://doi.org/10.1038/leu.2012.336	journal	November 2012
Immunotherapy for the treatment of multiple myeloma Jung, Sung-Hoon; Lee, Hyun-Ju; Vo, Manh-Cuong Critical Reviews in Oncology/Hematology, Vol. 111 https://doi.org/10.1016/j.critrevonc.2017.01.011	journal	March 2017
Clonal immunoglobulin light chain variable region germline gene use in AL amyloidosis: association with dominant amyloid-related organ involvement and survival after stem cell transplantation Comenzo, Raymond L.; Wally, Jeremy; Kica, Geraldina British Journal of Haematology, Vol. 106, Issue 3 https://doi.org/10.1046/j.1365-2141.1999.01591.x	journal	September 1999
Elevation of serum lactate dehydrogenase in AL amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation Muchtar, Eli; Dispenzieri, Angela; Lacy, Martha Q. British Journal of Haematology, Vol. 178, Issue 6 https://doi.org/10.1111/bjh.14830	journal	July 2017
The clinical value of the quantitative detection of four cancer-testis antigen genes in multiple myeloma Zhang, Yao; Bao, Li; Lu, Jin Molecular Cancer, Vol. 13, Issue 1 https://doi.org/10.1186/1476-4598-13-25	journal	January 2014
Light chain amyloidosis: Where are the light chains from and how they play their pathogenic role? Zhang, Chunlan; Huang, Xufei; Li, Jian Blood Reviews, Vol. 31, Issue 4 https://doi.org/10.1016/j.blre.2017.03.002	journal	July 2017
Lactate dehydrogenase as a prognostic marker in AL amyloidosis: expected or unexpected? Chim, Chor S. British Journal of Haematology, Vol. 178, Issue 6 https://doi.org/10.1111/bjh.14835	journal	July 2017
The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig VL germ line gene use and clonal plasma cell burden Comenzo, Raymond L.; Zhang, Yana; Martinez, Carmen Blood, Vol. 98, Issue 3 https://doi.org/10.1182/blood.V98.3.714	journal	August 2001
Correlates of immune and clinical activity of novel cancer vaccines van der Burg, Sjoerd H. Seminars in Immunology, Vol. 39 https://doi.org/10.1016/j.smim.2018.04.001	journal	October 2018
The clinical features and outcomes of systemic AL amyloidosis: a cohort of 231 Chinese patients Huang, X.; Wang, Q.; Jiang, S. Clinical Kidney Journal, Vol. 8, Issue 1 https://doi.org/10.1093/ckj/sfu117	journal	November 2014
Clarifying immunoglobulin gene usage in systemic and localized immunoglobulin light-chain amyloidosis by mass spectrometry Kourelis, Taxiarchis V.; Dasari, Surendra; Theis, Jason D. Blood, Vol. 129, Issue 3 https://doi.org/10.1182/blood-2016-10-743997	journal	January 2017
Targeting MAGE-C1/CT7 Expression Increases Cell Sensitivity to the Proteasome Inhibitor Bortezomib in Multiple Myeloma Cell Lines Carvalho, Fabricio de; Costa, Erico T.; Camargo, Anamaria A. PLoS ONE, Vol. 6, Issue 11 https://doi.org/10.1371/journal.pone.0027707	journal	November 2011
Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain–associated amyloidosis (AL) Abraham, Roshini S.; Geyer, Susan M.; Price-Troska, Tammy L. Blood, Vol. 101, Issue 10 https://doi.org/10.1182/blood-2002-09-2707	journal	May 2003
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis Gertz, Morie A.; Comenzo, Ray; Falk, Rodney H. American Journal of Hematology, Vol. 79, Issue 4 https://doi.org/10.1002/ajh.20381	journal	January 2005
Treatment of Immunoglobulin Light Chain Amyloidosis Dispenzieri, Angela; Buadi, Francis; Kumar, Shaji K. Mayo Clinic Proceedings, Vol. 90, Issue 8 https://doi.org/10.1016/j.mayocp.2015.06.009	journal	August 2015
Longitudinal Analysis and Prognostic Effect of Cancer-Testis Antigen Expression in Multiple Myeloma Atanackovic, D.; Luetkens, T.; Hildebrandt, Y. Clinical Cancer Research, Vol. 15, Issue 4 https://doi.org/10.1158/1078-0432.CCR-08-0989	journal	February 2009
New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes Palladini, Giovanni; Dispenzieri, Angela; Gertz, Morie A. Journal of Clinical Oncology, Vol. 30, Issue 36 https://doi.org/10.1200/JCO.2011.37.7614	journal	December 2012
MAGE-C2/CT10 Protein Expression Is an Independent Predictor of Recurrence in Prostate Cancer von Boehmer, Lotta; Keller, Lukas; Mortezavi, Ashkan PLoS ONE, Vol. 6, Issue 7 https://doi.org/10.1371/journal.pone.0021366	journal	July 2011
Expression and prognostic relevance of MAGE-C1/CT7 and MAGE-C2/CT10 in osteolytic lesions of patients with multiple myeloma Pabst, Caroline; Zustin, Jozef; Jacobsen, Frank Experimental and Molecular Pathology, Vol. 89, Issue 2 https://doi.org/10.1016/j.yexmp.2010.06.011	journal	October 2010
Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival Muchtar, E.; Dispenzieri, A.; Kumar, S. K. Leukemia, Vol. 31, Issue 1 https://doi.org/10.1038/leu.2016.140	journal	May 2016
Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains Sidana, S.; Tandon, N.; Dispenzieri, A. Leukemia, Vol. 32, Issue 3 https://doi.org/10.1038/leu.2017.286	journal	September 2017
Cancer-testis antigen expression and immunogenicity in AL amyloidosis Rosenzweig, M. A.; Landau, H.; Seldin, D. Blood Cancer Journal, Vol. 2, Issue 9 https://doi.org/10.1038/bcj.2012.32	journal	September 2012
Is immunotherapy here to stay in multiple myeloma? Rodríguez-Otero, Paula; Paiva, Bruno; Engelhardt, Monika Haematologica, Vol. 102, Issue 3 https://doi.org/10.3324/haematol.2016.152504	journal	January 2017
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management Kyle, R. A.; Durie, B. G. M.; Rajkumar, S. V. Leukemia, Vol. 24, Issue 6 https://doi.org/10.1038/leu.2010.60	journal	April 2010
Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis Comenzo, R. L.; Reece, D.; Palladini, G. Leukemia, Vol. 26, Issue 11 https://doi.org/10.1038/leu.2012.100	journal	April 2012
Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category Muchtar, E.; Dispenzieri, A.; Kumar, S. K. Leukemia, Vol. 31, Issue 7 https://doi.org/10.1038/leu.2016.369	journal	December 2016
Cancer testis antigen MAGE C1 can be used to monitor levels of circulating malignant stem cells in the peripheral blood of multiple myeloma patients Shires, Karen; Wienand, Kirsty Journal of Cancer Research and Clinical Oncology, Vol. 142, Issue 11 https://doi.org/10.1007/s00432-016-2231-3	journal	August 2016
Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells Atanackovic, D.; Hildebrandt, Y.; Jadczak, A. Haematologica, Vol. 95, Issue 5 https://doi.org/10.3324/haematol.2009.014464	journal	December 2009
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma Rajkumar, S. Vincent; Dimopoulos, Meletios A.; Palumbo, Antonio The Lancet Oncology, Vol. 15, Issue 12 https://doi.org/10.1016/S1470-2045(14)70442-5	journal	November 2014
Genome-wide analysis of cancer/testis gene expression Hofmann, O.; Caballero, O. L.; Stevenson, B. J. Proceedings of the National Academy of Sciences, Vol. 105, Issue 51 https://doi.org/10.1073/pnas.0810777105	journal	December 2008
T cell-based targeted immunotherapies for patients with multiple myeloma: Immunotargets in MM patients Wang, Lei; Jin, Nan; Schmitt, Anita International Journal of Cancer, Vol. 136, Issue 8 https://doi.org/10.1002/ijc.29190	journal	September 2014
MAGE-C1/CT7 and MAGE-C2/CT10 are frequently expressed in multiple myeloma and can be explored in combined immunotherapy for this malignancy de Carvalho, Fabricio; Alves, Veruska L. F.; Braga, Walter M. T. Cancer Immunology, Immunotherapy, Vol. 62, Issue 1 https://doi.org/10.1007/s00262-012-1376-4	journal	November 2012

Similar Records

Tertiary structure of human {Lambda}6 light chains.

Journal Article · 1999 · Amyloid : Int. J. Exp. Clin. Invest. · OSTI ID:942473

Pokkuluri, P R; Solomon, A; Weiss, D T; +2 more

Germ Line Origin and Somatic Mutations Determine the Target Tissues in Systemic AL-Amyloidosis

Journal Article · 2007 · PLoS ONE · OSTI ID:1627336

Enqvist, Stina; Sletten, Knut; Stevens, Fred J.; +2 more

Non-cardiac uptake of technetium-99m pyrophosphate in transthyretin cardiac amyloidosis

Journal Article · 2019 · Journal of Nuclear Cardiology (Online) · OSTI ID:22961970

Sperry, Brett W.; Gonzalez, Matthew H.; Brunken, Richard; +2 more

Title: MAGE genes: Prognostic indicators in AL amyloidosis patients

Citation Formats

References (32)

Similar Records

Related Subjects